24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial | Conference Material / Video | MSF Science Portal
Conference Material
|
Video
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
Berry C,
Motta I,
Kazounis E,
Fielding K,
Dodd M,
Nyang'wa BT,
Moodliar R
Share
Share
Similar Content
Abstract
|
Abstract
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Slide Presentation
|
Slide Presentation
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Loading...
Countries
Belarus
South Africa
Uzbekistan
Subject Area
antibiotic resistance
tuberculosis
antimicrobial resistance
Collections
TB-PRACTECAL Trial—Evidence for a shorter, safer, more effective treatment for drug-resistant tuberculosis
Languages
English
DOI
10.57740/atfr-ws57
Published Date
07 Jun 2022
Conference
MSF Scientific Days International 2022
Linked Content
Conference Material
|
Abstract
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
Conference Material
|
Slide Presentation
24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial
2022 May 11 • MSF Scientific Days International 2022
